Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Cork

Showing results (191-200 of 224) with videos related to

Pageof 23
Sort By:
Journal of Innate Immunity|September 4, 2010
Parameters governing invasive disease propensity of non-M1 serotype group A streptococciPeter G Maamary, Martina L Sanderson-Smith, Ramy K Aziz, et al.
The British Journal of Dermatology|October 10, 2019
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extensionM J Cork, D Thaçi, L F Eichenfield, et al.
The British Journal of Dermatology|October 1, 2020
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)A Wollenberg, A Blauvelt, E Guttman-Yassky, et al.
Nature Communications|October 7, 2020
Prophage exotoxins enhance colonization fitness in epidemic scarlet fever-causing Streptococcus pyogenesStephan Brouwer, Timothy C Barnett, Diane Ly, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 29, 2026
Dupilumab treatment restores epithelial barrier in nonlesional and lesional skin in children with atopic dermatitisMichael J Cork, Peck Y Ong, Simon G Danby, et al.
Lancet (London, England)|February 23, 2020
Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trialJoanne R Chalmers, Rachel H Haines, Lucy E Bradshaw, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 11, 2012
Tracing the evolutionary history of the pandemic group A streptococcal M1T1 clonePeter G Maamary, Nouri L Ben Zakour, Jason N Cole, et al.
Antibiotics (Basel, Switzerland)|April 23, 2022
Neurodegenerative Disease Treatment Drug PBT2 Breaks Intrinsic Polymyxin Resistance in Gram-Positive BacteriaDavid M P De Oliveira, Bernhard Keller, Andrew J Hayes, et al.
The New England Journal of Medicine|October 4, 2016
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisEric L Simpson, Thomas Bieber, Emma Guttman-Yassky, et al.
Journal of the American Academy of Dermatology|June 24, 2020
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trialAmy S Paller, Elaine C Siegfried, Diamant Thaçi, et al.
Pageof 23

Showing results (191-200 of 224) with videos related to

Sort By:
Pageof 23
Journal of Innate Immunity|September 4, 2010
Parameters governing invasive disease propensity of non-M1 serotype group A streptococciPeter G Maamary, Martina L Sanderson-Smith, Ramy K Aziz, et al.
The British Journal of Dermatology|October 10, 2019
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extensionM J Cork, D Thaçi, L F Eichenfield, et al.
The British Journal of Dermatology|October 1, 2020
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)A Wollenberg, A Blauvelt, E Guttman-Yassky, et al.
Nature Communications|October 7, 2020
Prophage exotoxins enhance colonization fitness in epidemic scarlet fever-causing Streptococcus pyogenesStephan Brouwer, Timothy C Barnett, Diane Ly, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 29, 2026
Dupilumab treatment restores epithelial barrier in nonlesional and lesional skin in children with atopic dermatitisMichael J Cork, Peck Y Ong, Simon G Danby, et al.
Lancet (London, England)|February 23, 2020
Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trialJoanne R Chalmers, Rachel H Haines, Lucy E Bradshaw, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 11, 2012
Tracing the evolutionary history of the pandemic group A streptococcal M1T1 clonePeter G Maamary, Nouri L Ben Zakour, Jason N Cole, et al.
Antibiotics (Basel, Switzerland)|April 23, 2022
Neurodegenerative Disease Treatment Drug PBT2 Breaks Intrinsic Polymyxin Resistance in Gram-Positive BacteriaDavid M P De Oliveira, Bernhard Keller, Andrew J Hayes, et al.
The New England Journal of Medicine|October 4, 2016
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisEric L Simpson, Thomas Bieber, Emma Guttman-Yassky, et al.
Journal of the American Academy of Dermatology|June 24, 2020
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trialAmy S Paller, Elaine C Siegfried, Diamant Thaçi, et al.
Pageof 23